LifeArc Ventures is a venture capital firm that finances and supports early-stage life science companies. The company aims to impact patients' lives positively by offering a combination of scientific, commercial, and financial support to innovative medical research projects.

LifeArc Ventures

LifeArc Ventures invests in early-stage science-led companies that can benefit from our advice, scientific insight and venture funding.
We’re committed to encouraging and financing innovative, early-stage life science companies to help them positively impact the lives of patients. As part of the medical research charity LifeArc, we offer a unique combination of scientific, commercial and financial support.
We have access to leading scientists with the skills and expertise to understand translational science at a deep level, enabling us to make educated and informed decisions around our investments, and to help our portfolio companies achieve meaningful progress

This week I completed my LifeArc AUTM Technology Transfer Fellowship, with a fabulous dinner and drinks reception at LifeArc's London rooftop garden, and talks hosted by Mathys & Squire LLP at the #Shard 🎉✨ 

What a year it has been! This fellowship gave me the opportunity to meet 16 other incredible fellows in the industry across the UK and Europe, who I am now proud to call my friends 🌟 

We were lucky enough to travel to the US for the AUTM Essentials course in Kansas City, the AUTM Annual Meeting in San Diego, and to Seville for the ASTP Annual Conference. With access to hundreds of webinars, inspiring talks from industry professionals, and mentoring support every month, it has truly been an invaluable experience 🌎 

Thank you Anji Miller Ph.D CLP RTTP for your earnest support over the last year, providing us with opportunities and experiences that I will never forget. Thanks also to RK Narayanan PhD MBA CLP, my professional mentor for all of your time and support, and my OUI managers Steve Silvey, Matthew Carpenter, RTTP and Simon Warner for enabling me to commit to this programme🤝 

This really has been one of the best years of my professional career. I look forward to putting my learning into practice and fostering these relationships. The future of Technology Transfer is bright!💡 

Charlotte Severn PhD Rita Moreno, PhD Sara de Jesus Baptista Lasani Wijetunge Michael Schrauben Hanna Milewicz Martine Ballinger Roxana Sava, PhD Nadine Conchinha, PhD Vikram Ratnu Inês Sobral Escoval Kristine C. Manuela Panić Isabel Christie Hritika Sharma, PhD Claudia A. 

#TechnologyTransfer #KnowledgeTransfer #StemCareers #ProfessionalDevelopment #Impact #Innovation #Fellowship

The 2024 MND Scotland and LifeArc jointly funded PhD Studentship call is open for applications right now!

Application deadline is 31 October 2024.
The award is up to £100,000 over 3 years.

For this call we're inviting projects aimed at improving the diagnosis pathway for MND or identifying biomarkers for use in MND research or care, from any discipline (e.g. fundamental research, engineering, etc.)

More information is available on the website - https://lnkd.in/efQaVjQT.

#MND #researchfunding #biomarkers

Congratulations to our portfolio company Surgery Hero. A £700k National Institute for Health and Care Research grant will help fund a 3-year randomised, controlled trial to assess the efficacy of Surgery Hero’s digital surgery clinic for patients undergoing elective hip or knee replacements. The study will look at long-term functional outcomes post-surgery, combining guidance, personalised health coaching, and a range digital resources to enhance patient outcomes and overall experience.

We're funding a new clinical trial to find out whether existing drugs can be repurposed to treat bronchiectasis – a "hidden" lung condition affecting over 200,000 people in the UK.

Despite being the third most common lung condition in the country, affecting people of all ages, there has historically been a lack of awareness of the condition. There are no specific treatments for bronchiectasis, and research and investment into new treatments has been limited.

Through the AIRNET (Anti-Inflammatory Repurposing Network) project, led by Professor James Chalmers at the University of Dundee, we're exploring the potential of repurposing 3 existing anti-inflammatory drugs to treat this condition. Patients across the UK will receive one of the 3 drugs and be monitored over a month at various trial sites to assess the drug's impact on lung inflammation.

Alongside funding, we're contributing our expertise in translational science to support this trial as part of our Chronic Respiratory Infection Translational Challenge.

If successful, this trial could significantly fast-track the availability of new treatments, offering hope to over 200,000 people who suffer from bronchiectasis in the UK.

Read more: https://t.ly/zhU5U

📢 New MedCity News article - Side Effects are Limiting GLP-1 Drug Efficacy: How Can Personalization Offer a Solution?
 
GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound have revolutionized the management of Type 2 diabetes and obesity, but are they living up to the hype? Recent real-world data suggests otherwise. 
 
Despite promising clinical trial results, many patients are discontinuing these therapies in part due to intolerable side effects. This discrepancy between clinical expectations and real-world outcomes raises critical questions: How can we ensure these life-changing drugs are both effective and accessible for all?
 
Our CEO Hakim Yadi Ph.D. OBE spoke to MedCity News about the urgent need to shift away from a one-size-fits-all approach and the role of digitization and machine learning in overcoming the challenges posed by GLP-1 therapies. 
 
The key to unlocking the full potential of these drugs lies in personalization — tailoring treatment plans to each patient's unique profile, optimizing dosage, minimizing side effects and integrating non-drug solutions.
 
By integrating advanced digital tools and machine learning, we can deliver personalized care at scale, allowing for precision dosing with minimal physician involvement. This not only maximizes drug efficacy but also enhances patient safety, ultimately leading to better health outcomes.
 
Read the full article and join the conversation on the future of personalized healthcare ➡ https://lnkd.in/dUTv8Fgj
 
#PrecisionCare #GLP1 #GLP1SideEffects #DigitalHealthcare #Healthcare

We are seeking a new Partnerships Operations Manager to support our Partnerships division!

In this role, you will support the work of the Partnerships team ensuring a high-quality, consistent approach to partnerships management and proposal development. You will also play a key role in preparing external proposals to support partnerships growth.  

More here: https://lnkd.in/eKfzbYCX

Skills and experience:
- Operations management in life sciences or healthcare.
- Knowledge of partnerships and alliances.
- CRM systems experience.
- Strong analytical and communication skills.
- Experience in scientific R&D healthcare organizations.
- Scientific undergraduate degree; advanced degree in science or business preferred.

What we offer:
We provide a supportive, inclusive environment with excellent growth opportunities and benefits such as flexible working options, a substantial pension scheme, private health insurance, and generous annual leave.

Why not take a sneak peak 👀 at the Future of #UK Life Sciences Regulation programme which has just been released👏 ➡️  https://ow.ly/KXNU50SWOGk

The Future of #UK Life Sciences Regulation will be returning to 📍 #London on 6 November 2024 💼 and expect discussions on the current and future 🚀 regulations for clinical trials in the UK, its appeal as a 🌍  faster regulatory pathways in the #UKHealthcare system, among other topics 👏 

For more information please visit ➡️ https://ow.ly/n7ky50SWOGl

#LifeSciencesRegulation

Watch the CheckRare interview below with Dr. Brad Elder to learn more about the Phase 1/2 ASPIRE-FTD clinical trial evaluating AVB-101, an investigational #GeneTherapy for people with #FrontotemporalDementia with GRN mutations.

Let me introduce the LifeArc Knowledge Transfer Fellows for 2024-2025. Join me in welcoming them and extending congratulations for securing a place on this competitive programme. The fellows are:

Eylem Aydogdu Lohaus, FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA (CRG) Barcelona, Spain
Gaston Sendin, DEBRA Austria
Amelie Franken, VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY), Belgium
Tania Chancellor, University of Cambridge, UK
Ana-Maria Ivanus, UCL, UK
Anastassia Kostenko, Newcastle University, UK
Kornelia Mikula, PhD, International Institute of Molecular and Cell Biology in Warsaw, Poland
Lucy Ahern, The Francis Crick Institute, UK
Eleonora Lugarà, UCL (UCL), UK
Maha A., The Babraham Institute Institute, UK
Sophie JEGOUIC, University of Reading, UK
Molly Steadman, Royal Holloway, University of London , UK
Avlokita Tiwari, University of Helsinki, Finland
Valwynne Faulkner, The Francis Crick Institute, UK
Ozan Cagil Deniz, IZMIR BIOMEDICINE AND GENOME CENTER (IBG), Turkey
Aaron Argomandkhah, Liverpool School of Tropical Medicine, UK
Fang Huang, University of Birmingham, UK

Over the next year, in collaboration with our partners including AUTM, ASTP, these fellows will be guided, trained, challenged and mentored as they progress and become future innovation leaders. Watch this space. Details of this fellowship programme can be found at this link https://lnkd.in/dWH6gfc2

#TechnologyTransfer #StemCareers #KnowledgeTransfer #Impact #ProfessionalDevelopment #KnowledgeExchange #Innovation #StemCareers #PhdCareers #CareersWithImpact #IntellectualProperty #EqualityDiversityInclusion #Mentorship #CelebrateYourSuccess #Fellowship #Proud

💡 New Discussion Paper: Health Coaching Scope of Practice 💡 

The UK & International Health Coaching Association (UKIHCA) has released a ground breaking discussion paper on health coaching, offering key insights and advancements in the field. 

At Surgery Hero, we follow UKIHCA guidelines closely to stay up to date with best practices and ensure the highest quality of care in our perioperative health coaching!

Keep reading to find out more about the key findings from this new paper:

🔍 Key Takeaways:

Empowering Patient Autonomy: Non-directive, evidence-based techniques help patients take control of their health for sustainable outcomes. This principle is at the heart of what we do at Surgery Hero. We empower our patients by providing personalised coaching that fosters independence and confidence in managing their health. 💪 

Integration with Healthcare Systems: Health coaches act as vital links between patients and healthcare providers, enhancing chronic condition management and perioperative care. At Surgery Hero, we are committed to creating seamless integration between our services and hospital care, bridging the gap with non-medical interventions that support our patients throughout their surgical journey. 🏥 📲 

Both of these key findings underscore the work we are already doing as part of our coaching process. By empowering patient autonomy and integrating healthcare systems, we aim to enhance our perioperative health coaching, leading to improved surgical outcomes and overall patient well-being. 💜 

📖 Read the full discussion paper here: https://lnkd.in/enNDYaRT

#HealthCoaching #PerioperativeCare #PatientEmpowerment

Metric
Company Name	LifeArc Ventures
Symbol
MSH ID	COM:LIFEARCVENTURES
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital in Life Sciences
Country	GB
Stage
Employee Count
Website	lifearcventures.com
LinkedIn	lifearc-ventures
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

LIFE

COM:LIFEARCVENTURES

LifeArc Ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue